Katalin "Kati" Karikó (Hungarian: Karikó Katalin, pronounced [ˈkɒrikoː ˌkɒtɒlin]; born 17 January 1955) is a Hungarian-American biochemist who specializes in ribonucleic acid (RNA)-mediated mechanisms, particularly in vitro-transcribed messenger RNA (mRNA) for protein replacement therapy. Karikó laid the scientific groundwork for mRNA vaccines, overcoming major obstacles and skepticism in the scientific community. Karikó received the Nobel Prize in Physiology or Medicine in 2023 for her work, along with American immunologist Drew Weissman.Karikó spent more than twenty years[when?] as a poorly supported researcher at the University of Pennsylvania, where she is an adjunct professor. Prior to winning the Nobel Prize, the University of Pennsylvania had demoted her, cut her pay, and described Karikó as "not of faculty quality"; she was never granted tenure. Karikó co-founded and was CEO of RNARx from 2006 to 2013. From 2013 to 2022, she was associated with BioNTech RNA Pharmaceuticals, first as a vice president and promoted to senior vice president in 2019. In 2022, she left BioNTech to devote more time to research. In 2021, she received an honorary doctorate from the University of Szeged in Hungary, where she has since become a professor.Karikó's work includes scientific research on RNA-mediated immune activation, resulting in the co-discovery with Drew Weissman of the nucleoside modifications that suppress the immunogenicity of RNA. This is seen as a further contribution to the therapeutic use of mRNA. Together with Weissman, she holds United States patents for the application of non-immunogenic, nucleoside-modified RNA. This technology has been licensed by BioNTech and Moderna to develop their protein replacement technologies, but it was also used for their COVID-19 vaccines.
Able to conduct pioneering medical research. Able to found and manage a commercial corporation, RNARx. Winner of the Nobel Prize in Medicine. But "not of faculty quality" in the eyes of the University of Pennsylvania administration. The Administration which just lost their President because she was unable to condemn antisemitism and authoritarian repression on campus.
People and institutions make mistakes all the time for more or less explicable reasons. This one looks like an egregious example. Perhaps it is. Perhaps there is a more complex story. Perhaps a case study for Kuhn's view of scientific progress.
No comments:
Post a Comment